vs
Side-by-side financial comparison of Webull Corp (BULL) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
Webull Corp is the larger business by last-quarter revenue ($131.5M vs $66.0M, roughly 2.0× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -21.5%, a 60.9% gap on every dollar of revenue. Webull Corp produced more free cash flow last quarter ($271.7M vs $43.5M).
Webull Corporation, often stylized as simply Webull, is a US-based financial services holding company headquartered in St. Petersburg, Florida. It provides an electronic trading platform of the same name.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
BULL vs SLNO — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $131.5M | $66.0M |
| Net Profit | $-28.3M | $26.0M |
| Gross Margin | — | 98.3% |
| Operating Margin | -16.3% | 33.5% |
| Net Margin | -21.5% | 39.4% |
| Revenue YoY | 46.3% | — |
| Net Profit YoY | -144.3% | 134.0% |
| EPS (diluted) | — | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $66.0M | ||
| Q2 25 | $131.5M | $32.7M | ||
| Q2 24 | $89.9M | — |
| Q3 25 | — | $26.0M | ||
| Q2 25 | $-28.3M | $-4.7M | ||
| Q2 24 | $-11.6M | — |
| Q3 25 | — | 98.3% | ||
| Q2 25 | — | 97.9% | ||
| Q2 24 | — | — |
| Q3 25 | — | 33.5% | ||
| Q2 25 | -16.3% | -20.0% | ||
| Q2 24 | -11.4% | — |
| Q3 25 | — | 39.4% | ||
| Q2 25 | -21.5% | -14.4% | ||
| Q2 24 | -12.9% | — |
| Q3 25 | — | $0.47 | ||
| Q2 25 | — | $-0.09 | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $476.7M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $751.6M | $494.8M |
| Total Assets | $2.6B | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $498.9M | ||
| Q2 25 | $476.7M | $286.8M | ||
| Q2 24 | — | — |
| Q3 25 | — | $494.8M | ||
| Q2 25 | $751.6M | $240.1M | ||
| Q2 24 | $-2.9B | — |
| Q3 25 | — | $599.9M | ||
| Q2 25 | $2.6B | $332.3M | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $272.1M | $43.5M |
| Free Cash FlowOCF − Capex | $271.7M | $43.5M |
| FCF MarginFCF / Revenue | 206.6% | 65.8% |
| Capex IntensityCapex / Revenue | 0.3% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $43.5M | ||
| Q2 25 | $272.1M | $-12.6M | ||
| Q2 24 | — | — |
| Q3 25 | — | $43.5M | ||
| Q2 25 | $271.7M | $-12.6M | ||
| Q2 24 | — | — |
| Q3 25 | — | 65.8% | ||
| Q2 25 | 206.6% | -38.6% | ||
| Q2 24 | — | — |
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q2 24 | — | — |
| Q3 25 | — | 1.67× | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
